Trial Profile
A study evaluating safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- 05 Nov 2010 New trial record.